Aleris Pharmaceuticals Limited
About Aleris Pharmaceuticals Limited
Data last updated:
Aleris Pharmaceuticals Limited is a public limited company based in Kolkata, West Bengal, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 13 May 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Kolkata, under CIN U24304WB2021PLC245141. Its GSTIN is 19ABGCS0615K1Z7 (West Bengal).
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors including Anand Kumar Parmanandka and Rubi Mukhopadhyay.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 55 B.R.B. Basu Road, Kolkata, West Bengal, India – 700001.
As per the financials filed for FY 2025, the company reported a revenue of ₹75.07 Cr. For the same year it recorded a net profit of ₹1.05 Cr (net margin 1.4%) and EBITDA of ₹2.83 Cr (EBITDA margin 3.8%).
As per MCA filings, the company has open charges of ₹20 Cr on record.
Company details
Contact details
Aleris Pharmaceuticals Limited's registered office is in Kolkata, West Bengal. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address55 B.R.B. Basu Road, Kolkata, West Bengal, India – 700001
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Aleris Pharmaceuticals Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activities of Aleris Pharmaceuticals are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and retail trading. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G2 | Retail Trading |
Financials of Aleris Pharmaceuticals Limited
FY 2025 filings availableAleris Pharmaceuticals Limited reported revenue of ₹75.07 Cr for FY 2025.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹2.83 Cr | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | ₹1.05 Cr | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 3.8% | |||
| Net Profit Margin | 1.4% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Aleris Pharmaceuticals Limited, buy the company report.
Board of directors of Aleris Pharmaceuticals Limited
Aleris Pharmaceuticals has 3 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anand Kumar Parmanandka Also directs: Alventa Pharma Limited, Elder Laboratories Limited, Nicholas Pharma India Limited and 3 more | Director | 13 May 2021 | 5 Years 5 Months | Current |
| Rubi Mukhopadhyay Also directs: Smith Stanistreet Pharmaceuticals LLP, Alventa Pharma Limited, Elder Laboratories Limited and 2 more | Director | 13 May 2021 | 5 Years 5 Months | Current |
| Biswajit Pan Also directs: Alventa Pharma Limited, Elder Laboratories Limited, Nicholas Pharma India Limited and 4 more | Director | 13 May 2021 | 5 Years 5 Months | Current |
Peer comparison
Aleris Pharmaceuticals Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Bennet Pharmaceuticals Limited | ₹75.82 Cr (FY 2025) | 11.0% | Vadodara, Gujarat, India | |||
| Aurochem Pharmaceuticals (India) Private Limited | ₹75.57 Cr (FY 2024) | 46.0% | Mumbai, Maharashtra, India | |||
| Meck Pharmaceuticals and Chemicals Private Limited | ₹75.11 Cr (FY 2025) | 18.0% | Ahmedabad, Gujarat, India | |||
| Aleris Pharmaceuticals Limitedthis company | ₹75.07 Cr (FY 2025) | ₹1.05 Cr | 1.4% | Kolkata, West Bengal, India | ||
| Casid Pharmaceuticals Private Limited | ₹74.41 Cr (FY 2025) | 28.0% | Manachanalloor, Tamil Nadu, India | |||
| Sreepathi Pharmaceuticals Limited | ₹74.26 Cr (FY 2025) | -17.0% | Telangana, India | |||
| Vance and Health Pharmaceuticals Private Limited | ₹72.08 Cr (FY 2025) | 17.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Aleris Pharmaceuticals Limited, buy the company report.
Auditor
Aleris Pharmaceuticals Limited is audited by H.P. JHUNJHUNWALA & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| H.P. JHUNJHUNWALA & CO. | FY 2023 | 302139E |
Shareholding
The shareholding of Aleris Pharmaceuticals Limited is on record for FY 2022, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2022 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Aleris Pharmaceuticals Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 11 Nov 2025 | 101189765 | Others | ₹20 Cr | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Aleris Pharmaceuticals Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Aleris Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Aleris Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 19ABGCS0615K1Z7 | West Bengal | Active | 09 Jul 2024 |
To see the full GST registrations and return filing status of Aleris Pharmaceuticals Limited, buy the company report.
Recent activity
Aleris Pharmaceuticals Limited has 3 board changes on record since 2021: 3 appointments. The latest: Anand Kumar Parmanandka was appointed as Director on 13 May 2021.
Frequently asked questions
Aleris Pharmaceuticals is an active public limited company based in Kolkata, West Bengal, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 13 May 2021 (5+ years old) and is registered under CIN U24304WB2021PLC245141.
Aleris Pharmaceuticals has 3 current directors:
- Anand Kumar Parmanandka - Director
- Rubi Mukhopadhyay - Director
- Biswajit Pan - Director
The latest financial statements of Aleris Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2022 are in the company report.
The GSTIN of Aleris Pharmaceuticals is 19ABGCS0615K1Z7, registered in West Bengal.
The CIN (Corporate Identification Number) of Aleris Pharmaceuticals is U24304WB2021PLC245141. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Aleris Pharmaceuticals was incorporated on 13 May 2021, making it 5+ years old. It is registered with the Registrar of Companies, Kolkata.
The peers of Aleris Pharmaceuticals by revenue are Bennet Pharmaceuticals Limited, Aurochem Pharmaceuticals (India) Private Limited, Meck Pharmaceuticals and Chemicals Private Limited, Casid Pharmaceuticals Private Limited, Sreepathi Pharmaceuticals Limited and 1 more, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Anand Kumar Parmanandka was appointed as Director on 13 May 2021. Biswajit Pan was appointed as Director on 13 May 2021. Rubi Mukhopadhyay was appointed as Director on 13 May 2021.
The registered office of Aleris Pharmaceuticals is at 55 B.R.B. Basu Road, Kolkata, West Bengal, India – 700001.
Aleris Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Aleris Pharmaceuticals has open charges of ₹20 Cr and no satisfied charges on record as per latest MCA filings.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
